HCT Subsidiary H&H Bio Finalizes HUMIC Absorption Merger... Establishes Integrated Non-Clinical CRO System

HCT's subsidiary, H&H Bio, announced that it has finalized the absorption-type merger with HUMIC, a company specializing in non-clinical efficacy evaluation.

This merger was carried out in a way that H&H Bio is the surviving company, while HUMIC was dissolved. After the merger, HCT continues to remain the largest shareholder.

Exterior view of H&H Bio

Through this integration, the two companies have established a comprehensive non-clinical CRO service system that covers everything from early-stage efficacy evaluation in new drug development to toxicity testing.

HUMIC is a company equipped with non-clinical efficacy evaluation using humanized mouse models and AI pathology analysis technology. In 2025, it recorded sales of 3.6 billion won and net income of 400 million won, continuing its trend of profitability.

H&H Bio has also shown rapid growth recently.

Its sales increased from 1.8 billion won in 2024 to 2.2 billion won in 2025. In the first quarter of 2026, it surged to 1.3 billion won, a 466% increase compared to the same period of the previous year.

With the combined capabilities of both companies, client companies are expected to reduce both new drug development timelines and management costs going forward. The company also anticipates further strengthening its business competitiveness and profitability by expanding package-type orders.

An official from HCT stated, "As the infrastructure buildout of H&H Bio is nearing completion, performance improvement is accelerating," adding, "Through this merger, we plan to accelerate the timeline for reaching the break-even point (BEP) in the bio business, and actively foster the company as a core driver of medium- to long-term growth."

This content was produced with the assistance of AI translation services.